Compare AU
Compare DRUG vs. GPEQ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the VanEck Global Listed Private Equity ETF (GPEQ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | GPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 30 |
Median incremental investment | $967.00 | $795.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,989.77 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | GPEQ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | GPEQ.AX was created on 2021-11-23 by VanEck. The fund's investment portfolio concentrates primarily on large cap equity. GPEQ.AX gives investors a diversified portfolio of the 50 largest and most liquid global listed private equity companies. GPEQ.AX aims to provide investment returns before fees and other costs which track the performance of the Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Blackstone Inc (9.71 %) Apollo Global Management Inc Class A (9.28 %) KKR & Co Inc Ordinary Shares (9.23 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Financials (100.00 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (70.14 %) Switzerland (8.64 %) Sweden (6.30 %) |
Management fee | 0.57 % | 0.65 % |
Key Summary
DRUG | GPEQ | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | LPX 50 Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.65 % |
Price | $8.12 | $26.01 |
Size | $191.120 million | $52.836 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 1.49 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 24/11/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | GPEQ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 30 |
Median incremental investment | $967.00 | $795.59 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,989.77 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | GPEQ | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | GPEQ |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |